Current situation of endemic mycosis in the Americas and the Caribbean: Proceedings of the first international meeting on endemic mycoses of the Americas (IMEMA)

Simple item page
dc.contributor.authorCaceres, Diego H.
dc.contributor.authorEcheverri Tirado, Laura C.
dc.contributor.authorBonifaz, Alexandro
dc.contributor.authorAdenis, Antoine
dc.contributor.authorGomez, Beatriz L.
dc.contributor.authorFlores, Claudia Lizette Banda
dc.contributor.authorCanteros, Cristina E.
dc.contributor.authorSantos, Daniel Wagner
dc.contributor.authorArathoon, Eduardo
dc.contributor.authorSoto, Elia Ramirez
dc.contributor.authorQueiroz-Telles, Flavio
dc.contributor.authorSchwartz, Ilan S.
dc.contributor.authorZurita, Jeannete
dc.contributor.authorDamasceno, Lisandra Serra
dc.contributor.authorGarcia, Nataly
dc.contributor.authorFernandez, Norma B.
dc.contributor.authorChincha, Omayra
dc.contributor.authorAraujo, Patricia
dc.contributor.authorRabagliati, Ricardo
dc.contributor.authorChiller, Tom
dc.contributor.authorGiusiano, Gustavo
dc.date.accessioned2025-01-20T21:03:21Z
dc.date.available2025-01-20T21:03:21Z
dc.date.issued2022
dc.description.abstractBackground The Americas are home to biologically and clinically diverse endemic fungi, including Blastomyces, Coccidioides, Emergomyces, Histoplasma, Paracoccidioides and Sporothrix. In endemic areas with high risk of infection, these fungal pathogens represent an important public health problem. Objectives This report aims to summarise the main findings of the regional analysis carried out on the status of the endemic mycoses of the Americas, done at the first International Meeting on Endemic Mycoses of the Americas (IMEMA). Methods A regional analysis for the Americas was done, the 27 territories were grouped into nine regions. A SWOT analysis was done. Results All territories reported availability of microscopy. Seventy percent of territories reported antibody testing, 67% of territories reported availability of Histoplasma antigen testing. None of the territories reported the use of (1-3)-beta-d-glucan. Fifty two percent of territories reported the availability of PCR testing in reference centres (mostly for histoplasmosis). Most of the territories reported access to medications such as trimethoprim-sulfamethoxazole, itraconazole, voriconazole and amphotericin B (AMB) deoxycholate. Many countries had limited access to liposomal formulation of AMB and newer azoles, such as posaconazole and isavuconazole. Surveillance of these fungal diseases was minimal. Conclusions A consensus emerged among meeting participants, this group concluded that endemic mycoses are neglected diseases, and due to their severity and lack of resources, the improvement of diagnosis, treatment and surveillance is needed.
dc.fuente.origenWOS
dc.identifier.doi10.1111/myc.13510
dc.identifier.eissn1439-0507
dc.identifier.issn0933-7407
dc.identifier.urihttps://doi.org/10.1111/myc.13510
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/93142
dc.identifier.wosidWOS:000840714400001
dc.issue.numero12
dc.language.isoen
dc.pagina.final1187
dc.pagina.inicio1179
dc.revistaMycoses
dc.rightsacceso restringido
dc.subjectblastomyces
dc.subjectcoccidioides
dc.subjecthistoplasma
dc.subjectparacoccidioides
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleCurrent situation of endemic mycosis in the Americas and the Caribbean: Proceedings of the first international meeting on endemic mycoses of the Americas (IMEMA)
dc.typeartículo
dc.volumen65
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas